SR9009
Also known as: stenabolic, Rev-ErbA agonist SR9009
Rev-ErbA agonist studied for circadian rhythm regulation, fat oxidation, and endurance in metabolic models.
Quick Reference
SR9009 - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemica compound, Agonist of Rev-ErbA
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. In an animal study, some of its effects were found to be independent of REV-ERB with an unknown mechanism of action.
Mechanism of Action
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. In an animal study, some of its effects were found to be independent of REV-ERB with an unknown mechanism of action.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
SR9009 (also known as stenabolic, Rev-ErbA agonist SR9009) is studied within the selective androgen receptor research community. Rev-ErbA agonist studied for circadian rhythm regulation, fat oxidation, and endurance in metabolic models.
Last updated October 28, 2026
Research status: limited. SR9009 appears across selective androgen receptor research forums and academic literature. Researchers note this compound falls in the sarms category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with SR9009. Comments are reviewed before appearing.